362 related articles for article (PubMed ID: 26138637)
21. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M; Skert C; Borlenghi E; Chiarini M; Cattaneo C; Morello E; Cancelli V; Cattina F; Cerqui E; Pagani C; Passi A; Ribolla R; Bernardi S; Giustini V; Lamorgese C; Ruggeri G; Imberti L; Caimi L; Russo D; Rossi G
Cancer Med; 2016 Feb; 5(2):265-74. PubMed ID: 26715369
[TBL] [Abstract][Full Text] [Related]
22. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
23. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
24. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
25. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
26. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
29. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
30. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
[TBL] [Abstract][Full Text] [Related]
31. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
[TBL] [Abstract][Full Text] [Related]
32. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
33. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival.
Jacobsohn DA; Tse WT; Chaleff S; Rademaker A; Duerst R; Olszewski M; Huang W; Chou PM; Kletzel M
Br J Haematol; 2009 Sep; 146(6):669-74. PubMed ID: 19650884
[TBL] [Abstract][Full Text] [Related]
34. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
[TBL] [Abstract][Full Text] [Related]
35. WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia.
Asghari-Ghomi A; Fallahian F; Garavand J; Mohammadi MH
Mol Biol Rep; 2024 Feb; 51(1):244. PubMed ID: 38300383
[TBL] [Abstract][Full Text] [Related]
36. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.
Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365
[TBL] [Abstract][Full Text] [Related]
37. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
38. [Correlation between clinical outcome and WT1 detection after hematopoietic stem cell transplantation in acute leukemia].
Zhao BR; Tang XW; Cen JN; Jin S; Shi XL; Wei XA; Chang WR; Sun AN; Wu DP
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1375-8. PubMed ID: 21756806
[TBL] [Abstract][Full Text] [Related]
39. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.
Kitamura K; Nishiyama T; Ishiyama K; Miyawaki S; Miyazaki K; Suzuki K; Masaie H; Okada M; Ogawa H; Imai K; Kiyoi H; Naoe T; Yokoyama Y; Chiba S; Hata T; Miyazaki Y; Hatta Y; Takeuchi J; Nannya Y; Kurokawa M; Ueda Y; Koga D; Sugiyama H; Takaku F
Int J Hematol; 2016 Jan; 103(1):53-62. PubMed ID: 26520650
[TBL] [Abstract][Full Text] [Related]
40. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
